Stellar Biotechnologies Appoints Herbert S. Chow, Ph.D., VP - Product Development
Port Hueneme, CA - May 18, 2010, Stellar Biotechnologies, Inc. (TSX-V: KLH) has appointed Herbert S. Chow, Ph.D., VP: Product Development.
Stellar’s CEO, Frank Oakes, said, “Stellar is very pleased to bring aboard a scientist with Dr. Chow’s strong, commercial market accomplishments in bringing diagnostic products from conception to high value sales, expanding revenues and profitability for the companies with which he has been involved. He has extensive experience with small companies as well as two of the most important names in ‘Big Pharma’, Abbott Labs and Johnson & Johnson. Dr. Chow will take a leadership role on the Stellar team, developing our primary immune response diagnostics product, and working closely with Daniel Morse, Ph.D. and Andrew Saxon, M.D. to expand our ideas of what growing role KLH will have in the future of medicine.”
Dr. Chow has held key business management and product development positions in new biologic devices, clinical diagnostic and consumer diagnostic markets. He has considerable operational expertise in developing and commercializing innovative technologies, and building successful strategic partnership in the fields of medical diagnostic and therapeutic devices. Previously, he held key senior management positions with start-up biotechnology companies, as well as international pharmaceutical companies Abbott Labs and Johnson & Johnson. Dr. Chow earned his BS in Microbiology and Immunochemistry at Ohio State University and his Ph.D. in Immunopathology at the University of Illinois. In more than 25 years in the life sciences, Dr. Chow has been granted nine patents in chemical processing, microfluidic devices, liquid sensing devices and medical devices for point-of-care diagnosis.
Dr. Chow said, “I am excited by the opportunity to take the lead in coordinating and executing Stellar’s commercialization plan. While we will initially focus on developing Stellar’s sustainable, high quality KLH in multiple vaccine markets, we will aggressively pursue KLH diagnostics for immune competence and companion diagnostics for biomarkers, which have the potential to dramatically impact the commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy and better economic efficiencies. I see this as an opportunity to build alliances between Stellar and pharmaceutical companies and academic institutions to broaden the company’s product base and strengthen its IP (Intellectual Property) portfolio to support rapid revenue growth”
Darrell Brookstein, VP
858 449 2523
About Stellar Biotechnologies, Inc (TSX-V: KLH): Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the blood of the rare keyhole limpet and Stellar has technology for the maintenance of that animal, as well as a non-lethal extraction method of the critical molecule and refinement process for KLH that it currently sells into growing academic, research, pharmaceutical markets.
Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.